Reply to S. Barni et Al and M. Sun et Al.

[1]  P. Karakiewicz,et al.  PISCES: a horoscope for first-line targeted therapy of metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Barni,et al.  PISCES trial: the end does not always justify the means. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Porta,et al.  Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[5]  Katherine Holmes,et al.  Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. , 2007, Cellular signalling.

[6]  C. Twelves,et al.  A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Godward,et al.  Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).